Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology
about
Factor XI and contact activation as targets for antithrombotic therapyCreating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug designSelection and characterization of a DNA aptamer inhibiting coagulation factor XIa.Factor XII as a Risk Marker for Hemorrhagic Stroke: A Prospective Cohort Study.Factor V Leiden thrombophilia.Genetic variants of coagulation factor XI show association with ischemic stroke up to 70 years of age.Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolismFactor XI antisense oligonucleotide for prevention of venous thrombosis.Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events.Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism.Prospective study of circulating factor XI and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).Lack of association of plasma factor XI with incident stroke and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) StudyFactor XI as a Therapeutic Target.Coagulation factor XII genetic variation, ex vivo thrombin generation, and stroke risk in the elderly: results from the Cardiovascular Health Study.Clotting factor changes during the first cycle of oral contraceptive use.Factor XII inhibition reduces thrombus formation in a primate thrombosis model.Factors XI and XII as Targets for New Anticoagulants.Using the laboratory to predict recurrent venous thrombosis.Tracking down contact activation - from coagulation in vitro to inflammation in vivo.The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.Relation of coagulation factor XI with incident coronary heart disease and stroke: the Cardiovascular Health Study.Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy.Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: An intriguing observation.Epidemiology of venous thromboembolism.Nasal angioma with osseous metaplasia.Coagulation procofactor activation by factor XIa.Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology.FXIII: mechanisms of action in the treatment of hemophilia A.Factor XI-related thrombosis and the role of concentrate treatment in factor XI deficiency.Correlation between factor (F)XIa, FIXa and tissue factor and trauma severity.New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds.Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent.The effect of time between venipuncture, processing and freezing on the measurement of coagulation factor levels
P2860
Q27024190-271A18AB-FD4D-47A9-B44F-61ED220C3A7FQ28543133-9036E30E-9A2B-474A-9CFE-F7B99074CEE1Q33704680-7795E787-3473-4D35-8C39-4A515B6C9048Q33706174-CF6B5B97-9D87-49E6-9975-34664B27E66AQ34152374-9E279FAE-7AEF-4723-8521-65DE5B1DFCCDQ35005516-AE8EEC9E-7BB9-40F8-AC60-223B9C987D01Q35032797-E3A745DF-D8AD-4288-99FD-701F00997182Q35200286-67C1C08E-D3FC-4236-9AC7-9B87E5B30351Q35293080-E69D4643-C9B0-4213-9A99-ABADC4FD4A7EQ35825548-48168B26-6EBA-4E23-835A-41B7875735F0Q36199721-00B1BB30-9C78-4C20-A475-156503519CEAQ36206122-C05CEA24-88FC-454C-8740-5B9068CD718DQ37033749-05B49930-3729-4C95-B2F9-D5C025E3FF7EQ37097019-A80F55F2-16F9-4602-879F-A376D81B33C2Q37216764-93F5D126-3B4C-4BA3-9180-7F404E31D290Q37636983-61DC3E82-2E9F-4B65-8520-26D5466060A6Q37662547-2CD32462-2179-4DEE-B419-6104ABEA4DEEQ37892665-218C265C-5009-4CF7-B9AB-EDD4DF5FE629Q38205955-AB2581F4-DF27-401F-8C59-E5F8FF44DD46Q38956551-61DA1C2D-3906-412A-AFCA-1FC74CC3A7BBQ39068765-972EA209-10A5-418A-B792-660A6E519270Q39175404-0E35B354-1EDF-4F9F-A1CE-4DB71D238DBEQ40001157-40C51F48-C57F-44A9-B281-FF9673288E05Q41667853-0398DE6C-9043-41F8-B074-F19B83BEEBE4Q42043368-1F64A452-3831-413C-9B42-A9EF22DA023EQ42141795-F7EB52BB-BF46-4C46-9091-042DED55EA76Q42365821-E5AF5973-7FC1-4126-80FD-798A5DA90AACQ45859215-234C5B4D-EF27-4821-9069-9C31EB304A5FQ45874796-79E55895-9BB2-4DEC-B04C-59263A101F28Q46774519-46A04C70-2103-4B10-AC90-FB60E87CAC39Q47791209-0D51A97A-83A3-489E-95A7-03D5C6A22EA5Q54049063-5A60D6BD-A1DD-4A87-8F89-D860928AFDF9Q57616424-1B6ADC8C-2724-4164-8DD1-A6AED0970266
P2860
Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Coagulation factors IX through ...... on of Thromboembolism Etiology
@en
Coagulation factors IX through ...... n of Thromboembolism Etiology.
@nl
type
label
Coagulation factors IX through ...... on of Thromboembolism Etiology
@en
Coagulation factors IX through ...... n of Thromboembolism Etiology.
@nl
prefLabel
Coagulation factors IX through ...... on of Thromboembolism Etiology
@en
Coagulation factors IX through ...... n of Thromboembolism Etiology.
@nl
P2860
P50
P1433
P1476
Coagulation factors IX through ...... on of Thromboembolism Etiology
@en
P2093
Ellen S O'Meara
P2860
P304
P356
10.1182/BLOOD-2009-05-219915
P407
P577
2009-07-17T00:00:00Z